In view of the potent synergistic effects of a cell depleting anti-CD4 mAb in combination with IL-21-based immunotherapy, in the Neuro2a tumor model20,21, we tested the combination of anti-PD-1 and anti-CD4 mAbs according to the schedule shown in Fig. 2b (inset). The gene discussed is CD4; the disease is neoplasm.